EUVIMEDOpdag EUVIMED
Klinische StudieOpen access · CC BY 4.0

Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss

Simon J Hume iD, Samuel Hall iD, Gareth Burns, Sara Vogrin, Daniel Tassone, Paul Desmond, Dilip Ratnam, Miriam T Levy iD, Rohit Sawhney, Amanda Nicoll iD, Zina Valaydon, Simone I Strasser and 7 more

Alimentary Pharmacology & Therapeutics · 2026-01 · 63 (2) · 231-241

DOI: 10.1111/apt.70332 ↗

At a glance

Klinische Studie in Alimentary Pharmacology & Therapeutics, published online on 2025-08-21. Written by Simon J Hume and 18 co-authors. Institution: St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia. Major MEDLINE topics: Antiviral Agents, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Nucleosides. Cited 4 times so far (Crossref); 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Health and Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Aims Discontinuing nucleos(t)ide analogues (NAs) may lead to functional cure (HBsAg loss) in selected patients with chronic hepatitis B (CHB). We evaluated the rates and predictors of HBsAg loss during long‐term follow‐up in a prospective cohort.

Methods

This real‐world extension study followed participants from a prospective trial of NA discontinuation. All patients had HBeAg‐negative CHB without cirrhosis. Efficacy outcomes (including HBsAg loss and decline) and safety outcomes [including hepatitis flare and hepatocellular carcinoma (HCC)] were evaluated.

Results

Amongst 97 participants (85% Asian), with a median follow‐up of 7 years, the cumulative incidence of HBsAg loss was 10%, 13% and 22% at 5, 7 and 9 years after stopping NA. HBsAg loss was associated with a lower end‐of‐treatment (EOT) HBsAg level (HR = 0.28, p < 0.001), older age (HR = 1.14, p = 0.005) and peak off‐treatment HBV DNA level (OR = 0.50, p = 0.002). Participants with EOT HBsAg level ≤ 10 IU/mL experienced early HBsAg loss (< 96 weeks) without ALT flares whilst those with EOT HBsAg level ≥ 10 IU/mL experienced late (≥ 96 weeks) HBsAg loss, often following ALT flares (5/8 cases). No cases of hepatic decompensation, liver transplantation or death occurred. Median liver stiffness did not increase. HCC was diagnosed in three individuals (4.4/1000 person‐years).

Conclusion

The rate of functional cure increased during long‐term follow‐up but remained low. EOT HBsAg strongly predicted the likelihood and timing of HBsAg loss. ALT flares were associated with HBsAg decline, and in some cases, with delayed HBsAg loss. Trial Registration: The clinical study was supported by the National Health and Medical Research Council of the study clinical trial ID is NCT02581033

Subjects

MeSH terms (MEDLINE)

Antiviral AgentsHepatitis B Surface AntigensHepatitis B, ChronicNucleosidesAdultAgedFemaleHumansMaleMiddle AgedCarcinoma, HepatocellularFollow-Up StudiesLiver NeoplasmsProspective StudiesTreatment Outcome

Author keywords

alt flarechronic hepatitis bfunctional curehbsag levelhbsag losshepatitis flarelong‐term follow‐upnucleos(t)ide analogue discontinuation

Substances

Antiviral AgentsHepatitis B Surface AntigensNucleosides

Authors and institutions

  • St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
  • University of Melbourne, Melbourne, Victoria, Australia.
  • Victorian Infectious Diseases Reference Laboratory, Melbourne, Victoria, Australia.
  • Western Health, Melbourne, Victoria, Australia.
  • Monash Health, Melbourne, Victoria, Australia.
  • Monash University, Melbourne, Victoria, Australia.

ORCID profiles: Simon J Hume, Samuel Hall, Miriam T Levy, Amanda Nicoll, Marie Sinclair, Jacinta A Holmes

Funding

  • National Health and Medical Research Council

Cite

APA

Hume, S. J., Hall, S., Burns, G., Vogrin, S., Tassone, D., Desmond, P., Ratnam, D., Levy, M. T., Sawhney, R., Nicoll, A., Valaydon, Z., Strasser, S. I., Ngu, M., Sinclair, M., Meredith, C., Matthews, G. V., Visvanathan, K., Holmes, J. A., & Thompson, A. J. (2026). Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss. Alimentary Pharmacology & Therapeutics, 63(2), 231-241. https://doi.org/10.1111/apt.70332

Vancouver

Hume SJ, Hall S, Burns G, Vogrin S, Tassone D, Desmond P, et al. Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss. Alimentary Pharmacology & Therapeutics. 2026;63(2):231-241. doi:10.1111/apt.70332

BibTeX
@article{Hume2026,
  author = {Hume, Simon J and Hall, Samuel and Burns, Gareth and Vogrin, Sara and Tassone, Daniel and Desmond, Paul and Ratnam, Dilip and Levy, Miriam T and Sawhney, Rohit and Nicoll, Amanda and Valaydon, Zina and Strasser, Simone I and Ngu, Meng and Sinclair, Marie and Meredith, Chris and Matthews, Gayle V and Visvanathan, Kumar and Holmes, Jacinta A and Thompson, Alexander J},
  title = {Long‐Term Follow‐Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {2},
  pages = {231--241},
  doi = {10.1111/apt.70332}
}
Start for free →